Shares of Soligenix, Inc. (SNGX) were rising more than 18 percent in pre-market on Tuesday to $3.82, after announcing positive data from a comparability study evaluating its HyBryte versus Valchlor in the treatment of cutaneous T-cell lymphoma (CTCL).
HyBryte is an ointment containing photosensitizer hypericin proposed to treat CTCL. Ceptaris Therapeutics' Valchlor is an approved treatment for mycosis fungoides-type cutaneous T-cell lymphoma.
In the comparative study, 60 percent of patients treated with HyBryte achieved 50 percent or more improvement in their mCAILS (modified Composite Assessment of Index Lesion Severity) score after 12 weeks, versus 20 percent treated with Valchlor.
"These results support the positive HyBryte data from the previously completed Phase 3 FLASH study and demonstrates that a relatively short treatment period with the drug can result in clinically meaningful outcomes," stated Christopher J. Schaber, President and Chief Executive Officer of Soligenix.
Soligenix shares had closed at $3.38, down 2.31 percent on Monday. The stock has traded in the range of $3.16 - 32.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.